-DOCSTART- -X- O
We -X- _ O
describe -X- _ O
the -X- _ O
production -X- _ O
and -X- _ O
characterization -X- _ O
of -X- _ O
human -X- _ B-Intervention
monoclonal -X- _ I-Intervention
antibodies -X- _ I-Intervention
( -X- _ I-Intervention
mAb -X- _ I-Intervention
) -X- _ I-Intervention
specific -X- _ I-Intervention
for -X- _ I-Intervention
the -X- _ I-Intervention
major -X- _ I-Intervention
hepatitis -X- _ I-Intervention
B -X- _ I-Intervention
virus -X- _ I-Intervention
( -X- _ I-Intervention
HBV -X- _ I-Intervention
) -X- _ I-Intervention
S -X- _ I-Intervention
protein. -X- _ I-Intervention
The -X- _ O
mAbs -X- _ O
, -X- _ O
two -X- _ O
IgG1κ -X- _ O
and -X- _ O
one -X- _ O
IgG1λ -X- _ O
, -X- _ O
were -X- _ O
secreted -X- _ O
by -X- _ O
B-cell -X- _ O
clones -X- _ O
obtained -X- _ O
from -X- _ O
peripheral -X- _ O
blood -X- _ O
mononuclear -X- _ O
cells -X- _ O
( -X- _ O
PBMC -X- _ O
) -X- _ O
of -X- _ O
one -X- _ B-Patient
person -X- _ I-Patient
convalescent -X- _ I-Patient
from -X- _ I-Patient
acute -X- _ I-Patient
hepatitis -X- _ I-Patient
B -X- _ I-Patient
and -X- _ I-Patient
one -X- _ I-Patient
vaccinated -X- _ I-Patient
individual. -X- _ I-Patient
The -X- _ O
former -X- _ O
recognized -X- _ O
a -X- _ O
denaturation-insensitive -X- _ O
epitope -X- _ O
within -X- _ O
the -X- _ O
p24 -X- _ O
protein -X- _ O
whereas -X- _ O
the -X- _ O
latter -X- _ O
recognized -X- _ O
a -X- _ O
denaturation-sensitive -X- _ O
, -X- _ O
conformational -X- _ O
epitope -X- _ O
located -X- _ O
within -X- _ O
the -X- _ O
HBsAg -X- _ O
common -X- _ O
“a” -X- _ O
determinant. -X- _ O
This -X- _ O
mAb -X- _ O
, -X- _ O
denominated -X- _ O
ADRI-2F3 -X- _ O
, -X- _ O
displayed -X- _ O
a -X- _ O
very -X- _ O
high -X- _ O
protective -X- _ B-Outcome
titer -X- _ I-Outcome
of -X- _ I-Outcome
over -X- _ I-Outcome
43,000 -X- _ I-Outcome
IU -X- _ I-Outcome
/ -X- _ I-Outcome
mg -X- _ I-Outcome
mAb -X- _ I-Outcome
and -X- _ I-Outcome
showed -X- _ I-Outcome
an -X- _ I-Outcome
extremely -X- _ I-Outcome
potent -X- _ I-Outcome
neutralizing -X- _ I-Outcome
activity -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
in -X- _ I-Outcome
vitro -X- _ I-Outcome
model -X- _ I-Outcome
of -X- _ I-Outcome
HBV -X- _ I-Outcome
infection -X- _ I-Outcome
using -X- _ I-Outcome
primary -X- _ I-Outcome
hepatocytes -X- _ I-Outcome
from -X- _ I-Outcome
Tupaia -X- _ I-Outcome
belangeri -X- _ I-Outcome
as -X- _ I-Outcome
target. -X- _ I-Outcome
Recombinant -X- _ O
variable -X- _ O
heavy -X- _ O
and -X- _ O
light -X- _ O
domain -X- _ O
sequences -X- _ O
derived -X- _ O
from -X- _ O
mAb -X- _ O
ADRI-2F3 -X- _ O
were -X- _ O
cloned -X- _ O
into -X- _ O
eukaryotic -X- _ O
expression -X- _ O
vectors -X- _ O
and -X- _ O
showed -X- _ O
identical -X- _ O
fine -X- _ O
specificity -X- _ O
and -X- _ O
1 -X- _ O
log -X- _ O
( -X- _ O
10 -X- _ O
) -X- _ O
higher -X- _ O
titer -X- _ O
than -X- _ O
the -X- _ O
original -X- _ O
IgG1λ. -X- _ O
It -X- _ O
is -X- _ O
envisaged -X- _ O
that -X- _ O
such -X- _ O
mAb -X- _ O
will -X- _ O
be -X- _ O
able -X- _ O
to -X- _ O
efficiently -X- _ O
prevent -X- _ O
HBV -X- _ O
reinfection -X- _ O
after -X- _ O
liver -X- _ O
transplantation -X- _ O
for -X- _ O
end-stage -X- _ O
chronic -X- _ O
HBV -X- _ O
infection -X- _ O
or -X- _ O
infection -X- _ O
after -X- _ O
needle-stick -X- _ O
exposure -X- _ O
, -X- _ O
providing -X- _ O
an -X- _ O
unlimited -X- _ O
source -X- _ O
of -X- _ O
valuable -X- _ O
protective -X- _ O
anti-HBs -X- _ O
antibody -X- _ O
. -X- _ O

